GLP-1 maintenance dosing for PCOS: what two years actually looks like
Quick answer
The creator appears to be on tirzepatide based on the 10 mg and 12.5 mg dose references, using an off-label every-nine-to-ten-day schedule under endocrinologist supervision for PCOS management and weight maintenance. Her reported symptom return with longer intervals is consistent with semaglutide and tirzepatide pharmacokinetics, where trough plasma levels drop meaningfully beyond seven to ten days. Recent bloodwork showing mildly elevated testosterone and low estrogen suggests her PCOS is partially but not fully controlled at current dosing frequency.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @itsmekelsc actually say?
The creator describes two years of weight maintenance on a GLP-1 medication, staying at roughly 10 milligrams and dosing every nine to ten days rather than the standard weekly schedule. She credits this approach with keeping her PCOS symptoms, including cycle irregularity and inflammation, under control. She's transparent that her endocrinologist guides her protocol and that recent bloodwork showed slightly elevated testosterone and low estrogen, which she describes as typical for PCOS.
She also pushes back on the idea that maintenance always means reducing your dose or stretching out injections, saying, "maintenance looks so different for everyone." She eats three meals a day, doesn't count calories, and aims for around 100 grams of protein. The overall tone is personal anecdote with a consistent disclaimer to talk to your doctor, which is more responsible than most GLP-1 content on TikTok.
Does the science back this up?
The off-label dosing interval is the most medically interesting part here, and there's actually some pharmacokinetic logic behind it. Most evidence supports weekly dosing, but individual variation in drug clearance is real.
GLP-1 receptor agonists like semaglutide have a half-life of approximately seven days, which is why weekly dosing is standard for products like Ozempic and Wegovy. Stretching to 10 days could theoretically allow trough levels to drop low enough for symptoms to return, which tracks with her observations. A 2022 pharmacokinetic review in Clinical Pharmacokinetics (Overgaard et al.) confirmed that semaglutide's steady-state levels drop significantly beyond seven days in some patients.
On the PCOS side, GLP-1 receptor agonists have shown genuine promise. A 2023 randomized trial published in Fertility and Sterility (Elkind-Hirsch et al.) found that GLP-1 therapy improved menstrual regularity and reduced androgen levels in women with PCOS and obesity. Her observation that longer dosing gaps trigger cycle disruption is biologically plausible given this mechanism.
What did they get wrong (or right)?
She gets credit for accuracy on the PCOS-GLP-1 connection. The science does support her experience. Where she's on shakier ground is implying that her specific dosing schedule, 10 mg every nine to ten days, is something others might replicate. It is not a validated protocol.
The 10 mg figure is also worth pausing on. This likely refers to tirzepatide (Mounjaro or Zepbound), which is dosed at 5, 7.5, 10, 12.5, and 15 mg. That's a meaningful detail she doesn't clarify, and 104,000 viewers guessing at which drug she's on is a real problem. Dose numbers mean nothing without knowing the medication.
Her bloodwork comment is actually a point in her favor. She's not ignoring the hormonal signal, she's reporting it. But casually noting "my testosterone is a little elevated" while simultaneously extending dosing intervals sends mixed messages. If her endocrinologist is recommending every 10 days and she's stretching to two weeks, that's not maintenance optimization, that's non-adherence with acknowledged consequences.
What should you actually know?
GLP-1 medications are not one-size-fits-all, and maintenance dosing genuinely varies by individual. That part of her message is sound. But the specifics she shares, dose numbers, injection intervals, symptom responses, are her data points from her body under her doctor's supervision. They should not be treated as a template.
PCOS is a real and under-treated condition, and GLP-1 receptor agonists are being studied seriously for it. A 2021 meta-analysis in Obesity Reviews (Liu et al.) found GLP-1 agonists significantly reduced BMI, fasting insulin, and testosterone in women with PCOS. The mechanism likely involves insulin sensitization and reduced ovarian androgen production, not a direct hormonal fix.
If you have PCOS and are considering or currently on a GLP-1, the takeaway from this video should be: work with an endocrinologist, track your symptoms, and get bloodwork done regularly. Do not self-adjust your dosing schedule based on someone else's maintenance routine.
Bottom line
This video is more responsible than average. The creator isn't selling anything, repeatedly defers to her doctor, and shares real clinical data including her bloodwork. The core message that maintenance is individualized and PCOS can affect your GLP-1 needs is supported by evidence. The risk is in the specifics: viewers may latch onto her dose number or injection interval without the clinical context that makes those numbers meaningful for her specifically.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1 maintenance dosing for PCOS: what two years actually looks like, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
GLP-1 maintenance dosing for PCOS: what two years actually looks like should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
The creator appears to be on tirzepatide based on the 10 mg and 12.
FormBlends verdict
The creator appears to be on tirzepatide based on the 10 mg and 12.5 mg dose references, using an off-label every-nine-to-ten-day schedule under endocrinologist supervision for PCOS management and weight maintenance. Her reported symptom return with longer intervals is consistent with semaglutide and tirzepatide pharmacokinetics, where trough plasma levels drop meaningfully beyond seven to ten days. Recent bloodwork showing mildly elevated testosterone and low estrogen suggests her PCOS is partially but not fully controlled at current dosing frequency.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator appears to be on tirzepatide based on the 10 mg and 12.5 mg dose references, using an off-label every-nine-to-ten-day schedule under endocrinologist supervision for PCOS management and weight maintenance. Her reported symptom return with longer intervals is consistent with semaglutide and tirzepatide pharmacokinetics, where trough plasma levels drop meaningfully beyond seven to ten days. Recent bloodwork showing mildly elevated testosterone and low estrogen suggests her PCOS is partially but not fully controlled at current dosing frequency.
- GLP-1 receptor agonists like semaglutide have a half-life of approximately 7 days, meaning trough levels can drop significantly beyond that window, which may explain symptom return at longer dosing intervals (Overgaard et al., 2022, Clinical Pharmacokinetics).
- A 2023 RCT in Fertility and Sterility found GLP-1 therapy improved menstrual regularity and reduced testosterone in women with PCOS and obesity, supporting the creator's reported hormone-related benefits.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- GLP-1 receptor agonists like semaglutide have a half-life of approximately 7 days, meaning trough levels can drop significantly beyond that window, which may explain symptom return at longer dosing intervals (Overgaard et al., 2022, Clinical Pharmacokinetics).
- A 2023 RCT in Fertility and Sterility found GLP-1 therapy improved menstrual regularity and reduced testosterone in women with PCOS and obesity, supporting the creator's reported hormone-related benefits.
- The STEP 4 trial (Rubino et al., 2021, JAMA) showed that patients who discontinued semaglutide after weight loss regained roughly two-thirds of lost weight within a year, supporting the case for long-term maintenance dosing in some patients.
- Dose numbers mean nothing without the drug name. 10 mg is a mid-range maintenance dose for tirzepatide but is not a standard unit for semaglutide, liraglutide, or other GLP-1 agents.
- Mildly elevated testosterone while on GLP-1 therapy is not simply normal for PCOS patients. It may indicate the current protocol is not fully controlling androgen excess, which has implications beyond weight.
- A 2021 meta-analysis in Obesity Reviews (Liu et al.) found GLP-1 agonists significantly reduced BMI, fasting insulin, and testosterone in PCOS patients, likely through insulin sensitization rather than direct hormonal action.
- Custom dosing intervals like every nine to ten days are not FDA-approved schedules and should only be managed by a prescribing physician with regular bloodwork monitoring.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Kelsey Martinez · TikTok creator
104.9K views on this video
My dose and experience in maintenance on a glp1 for 2 years! #pcos #fyp
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Kelsey Martinez, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.